What Changed
Price Move History
- Daily moves over 5%
- 16 252 sessions, November 20, 2025 to November 20, 2026
- Largest daily move
- +35.8% close of November 9, 2026
- 1-year change
- +129.4% closing prices, November 20, 2025 to November 20, 2026
- 1-month change
- +27.3% closing prices, October 20, 2026 to November 20, 2026
Company Description
Delcath Systems Inc (Nasdaq: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. Operating in the surgical and medical instrument manufacturing industry within the broader manufacturing sector, Delcath develops and commercializes proprietary drug–device technologies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects.
The company’s business centers on its hepatic delivery technologies, which are used in a procedure known as percutaneous hepatic perfusion (PHP). According to company disclosures, Delcath operates through a single reportable segment that encompasses the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific liver-related conditions. The company conducts business in the United States and Europe.
Core products and technology
Delcath’s proprietary products are HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan. Both are designed to administer high-dose melphalan chemotherapy to the liver during a PHP procedure while controlling systemic exposure.
- HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System): In the United States, HEPZATO KIT is treated as a combination drug and device product and is regulated and approved for sale as a drug by the U.S. Food and Drug Administration (FDA. The kit combines the chemotherapeutic drug melphalan with Delcath’s proprietary Hepatic Delivery System (HDS).
- CHEMOSAT Hepatic Delivery System (HDS) for Melphalan: In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT. It has been used at major medical centers in percutaneous hepatic perfusion procedures to treat a range of cancers of the liver.
The HDS component is used to isolate hepatic venous blood from the systemic circulation while simultaneously filtrating the hepatic venous blood during melphalan infusion and washout. Company materials state that this approach results in loco-regional delivery of a relatively high melphalan dose that can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduced systemic exposure.
Therapeutic focus and indications
Delcath’s primary therapeutic focus is on metastatic uveal melanoma (mUM) and other cancers involving the liver. The company describes itself as focused on the treatment of primary and metastatic liver cancers, with a particular emphasis on liver-dominant metastatic disease.
In the United States, HEPZATO KIT is approved as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. The company notes that full prescribing information, including a boxed warning, applies to the product.
In Europe, CHEMOSAT has been used in PHP procedures at major medical centers to treat a wide range of cancers of the liver. Published data cited in company news releases describe use of CHEMOSAT in liver-dominant metastatic uveal melanoma and other liver metastases, with studies examining survival outcomes, disease control, and the role of repeated PHP cycles.
Clinical evidence and research activity
Delcath’s technologies are supported by a body of clinical and real-world evidence referenced in its public communications. The company highlights:
- A Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma, which led to the FDA approval of HEPZATO. Subgroup analyses of this study have been published, assessing efficacy and safety across factors such as age, sex, geographic region, tumor burden, extent of liver involvement, extrahepatic lesions, baseline LDH, and prior therapies.
- The CHOPIN Phase 2 trial, sponsored by Leiden University Medical Center, evaluating CHEMOSAT with the immune checkpoint inhibitors ipilimumab and nivolumab in metastatic uveal melanoma. Company disclosures report a significant improvement in one-year progression-free survival for the combination versus CHEMOSAT alone.
- A 10-year single-center experience from Asklepios Hospital Barmbek in Hamburg, Germany, using CHEMOSAT for liver-dominant metastatic uveal melanoma, reporting safety and efficacy outcomes over multiple PHP procedures.
- A retrospective analysis from the University of Tübingen examining long-term survivors with liver metastases from uveal melanoma, which underscores the potential benefits of early use of liver-directed therapies, including PHP, in achieving long-term survival.
- An expert narrative review in the Journal of Vascular and Interventional Radiology summarizing the rationale, technique, patient selection, clinical outcomes, and research directions for PHP with melphalan using HEPZATO KIT, and emphasizing its role as an FDA-approved liver-directed therapy for unresectable hepatic metastases from uveal melanoma with limited extrahepatic disease.
These publications and analyses, as described in Delcath’s news releases, collectively present data on objective response rates, progression-free survival, overall survival, disease control rates, safety profiles, and the impact of tumor burden and treatment sequencing on outcomes in metastatic uveal melanoma and liver-dominant disease.
Geographic footprint and regulatory status
Delcath reports that it operates its business in the United States and Europe. In the U.S., HEPZATO KIT is FDA-approved and regulated as a drug–device combination product. In Europe, the CHEMOSAT Hepatic Delivery System is regulated as a Class III medical device and approved for sale under the CHEMOSAT trade name.
The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Capital Market under the symbol DCTH, as confirmed in multiple Form 8-K filings. These filings also show that Delcath is incorporated in Delaware and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC).
Corporate and financial reporting
Delcath communicates its financial and operational performance through press releases and SEC filings, including Form 8-K reports on quarterly results, preliminary financial updates, and other material events. Recent disclosures describe product revenue derived from HEPZATO KIT in the United States and CHEMOSAT in Europe, as well as information on gross margins, operating expenses, and cash and investment balances. The company also reports on non-GAAP measures such as adjusted EBITDA and explains the rationale for presenting these metrics alongside GAAP results.
In addition, Delcath has disclosed the authorization of a share repurchase program under which the board of directors approved the repurchase of up to a specified dollar amount of outstanding common stock, subject to market conditions. The company has also reported equity inducement grants under a stock incentive plan, consistent with Nasdaq listing rules.
Governance and regulatory disclosures
Delcath’s SEC filings indicate ongoing corporate governance activity, including amendments and restatements of its bylaws. An 8-K filing describes updates to advance notice provisions for stockholder nominations and proposals, officer and chairperson election provisions, indemnification rights for directors, officers and other agents, and various administrative and clarifying changes.
The company’s filings also include standard forward-looking statement disclosures under the Private Securities Litigation Reform Act of 1995, noting that certain statements about financial outlook, clinical development, and business plans are subject to risks and uncertainties.
Position within the medical device and oncology landscape
Within the broader manufacturing sector, Delcath is classified in surgical and medical instrument manufacturing, with a specialized focus on interventional oncology and liver-directed therapies. Its business model centers on proprietary hepatic delivery systems and associated drug–device combinations used in PHP procedures for patients with liver metastases, particularly metastatic uveal melanoma.
By concentrating on loco-regional chemotherapy delivery to the liver and supporting this approach with clinical trials, retrospective analyses, and expert reviews, Delcath positions its technologies as options for managing liver-dominant metastatic disease in settings where systemic exposure to chemotherapy must be controlled. The company’s disclosures emphasize the potential for high-dose melphalan delivery with controlled systemic exposure, the role of PHP in multimodal treatment strategies, and the use of its products at specialized centers in the U.S. and Europe.
Stock Performance
Delcath Systems (DCTH) closed at $18.79 on November 20, 2026. Over the past 12 months, the price has gained 129.4%.
DCTH Metrics & Rankings
Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Delcath Systems has 10 recent news articles, with the latest published on . Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, conferences, earnings date. View all DCTH news →
SEC Filings
Delcath Systems has filed 10 recent SEC filings, including 3 Form 8-K, 2 Form 4, 2 Form 10-Q, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DCTH SEC filings →
Insider Radar
Insider selling at Delcath Systems over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Delcath Systems generated $85.2M in revenue in FY2025, retaining a 86.2% gross margin, operating income reached $660K (0.8% operating margin), and net income was $2.7M, reflecting a 3.2% net profit margin. Diluted earnings per share stood at $0.07. The company generated $22.5M in operating cash flow. The current ratio was 10.92, measuring current assets divided by current liabilities.
Upcoming Events
Cholangiocarcinoma IND filing
RSU vesting — 1st installment
RSU vesting (one-third)
RSU first vesting
RSU first vesting
RSU vesting — 2nd installment
RSU vesting (second tranche)
RSU second vesting
Overall survival data
RSU second vesting
Primary endpoint results
Overall survival results
RSU vesting — 3rd installment
RSU vesting (final tranche)
RSU vesting completion
RSU final vesting
RSU final vesting
Option expiration
Delcath Systems has 18 upcoming scheduled events. The next event, "Cholangiocarcinoma IND filing", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the DCTH stock price.
Short Interest History
Short interest in Delcath Systems (DCTH) currently stands at 1.8 million shares, down 5.7% from the previous reporting period, representing 5.4% of the float. Since November 2025, short interest has decreased by 59.0%.
Days to Cover History
Days to cover for Delcath Systems (DCTH) currently stands at 5.7 days, down 8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 22.9%. Across the settlements charted above, it has ranged from 2.3 to 13.8 days.
DCTH Company Profile & Sector Positioning
Delcath Systems (DCTH) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing DCTH often look at related companies in the same sector, including Beta Bionics, Inc. (BBNX), Bioventus Inc. (BVS), Tactile Systems Technology, Inc. (TCMD), Sight Sciences, Inc. (SGHT), and Varex Imaging Corporation (VREX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DCTH's relative position within its industry.